

Acute Lymphoblastic Leukemia (ALL) (short version)

Recommendations from the society for diagnosis and therapy of
haematological and oncological diseases

Publisher

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Bauhofstr. 12
D-10117 Berlin

Executive chairman: Prof. Dr. med. Hermann Einsele

Phone: +49 (0)30 27 87 60 89 - 0

info@dgho.de

www.dgho.de

Contact person

Prof. Dr. med. Bernhard Wörmann
Medical superintendent

Source

www.onkopedia-guidelines.info

The information of the DGHO Onkopedia Web Site is not intended or implied to be a substitute for professional medical advice or medical care. The advice of a medical professional should always be sought prior to commencing any form of medical treatment. To this end, all component information contained within the web site is done so for solely educational purposes. DGHO Deutsche Gesellschaft für Hämatologie und Onkologie and all of its staff, agents and members disclaim any and all warranties and representations with regards to the information contained on the DGHO Web Site. This includes any implied warranties and conditions that may be derived from the aforementioned web site information.

Table of contents

1 Summary	2
2 Therapy	2
15 Authors' Affiliations	4
16 Disclosures	6

Acute Lymphoblastic Leukemia (ALL) (short version)

ICD-10: D61.-

Date of document: May 2022

Compliance rules:

- [Guideline](#)
- [Conflict of interests](#)

Authors: Nicola Gökbüget, Nicola Gökbüget, Claudia Baldus, Monika Brüggemann, Alexander W. Hauswirth, Urs Schanz, Sigrid Machherndl-Spandl, Matthias Stelljes, Max Topp

1 Summary

Acute lymphoblastic leukemia (ALL) is a rare malignant hematologic disorder. The peak incidence is in childhood. These recommendations refer to ALL in adults.

The clinical picture of ALL is characterized by proliferation and accumulation of malignant degenerate immature lymphoid blasts in bone marrow, blood, lymphoid and non-lymphoid tissues. Untreated, the disease leads to death within a few months.


Biologically, ALL is heterogeneous. Genetic and immunophenotypic markers have prognostic significance and are now also predictive for subgroup-specific therapy.

Treatment has curative intent. The standard is established by the studies and expert recommendations of GMALL (German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia). Long-term survival rates in adults have improved over the last decades and with the current concept for patients up to the age of 55 years are about 60-70% with large variations depending on age and risk group.

2 Therapy

The current treatment algorithm is depicted in [Figure 1](#) and [Figure 2](#).

Figure 1: Therapy structure in adults with acute lymphoblastic leukemia, Ph-negative



Legend:

— curative treatment intent;


¹ ALL – acute lymphoblastic Leukemia, LBL – lymphoblastic lymphoma;

² MRD – quantification of minimal residual disease;

³ decision to patient’s individual requirement;

⁴ indication and conditioning regimen dependent on biological age and fitness

Figure 2: Therapy structure in adults with acute lymphoblastic leukemia, Ph-positive



Legend:

— curative treatment intent;

¹ ALL – acute lymphoblastic Leukemia, LBL – lymphoblastic lymphoma;

² MRD – quantification of minimal residual disease;

³ indication and conditioning regimen adapted to patient's biological age;

⁴ TKI after SCT either MRD-based or preventive

15 Authors' Affiliations

Dr. med. Nicola Gökbuget

Johann Wolfgang Goethe-Universität
Medizinische Klinik II
Abteilung Hämatologie und Onkologie
Theodor-Stern-Kai 7
60590 Frankfurt
goekbuget@em.uni-frankfurt.de

Dr. med. Nicola Gökbuget

Johann Wolfgang Goethe-Universität
Medizinische Klinik II
Abteilung Hämatologie und Onkologie
Theodor-Stern-Kai 7
60590 Frankfurt
goekbuget@em.uni-frankfurt.de

Prof. Dr. med. Claudia Baldus

Universitätsklinikum Schleswig-Holstein
Klinik für Innere Medizin II
Hämatologie und Onkologie
Arnold-Heller-Str. 3
24105 Kiel
Claudia.Baldus@uksh.de

Prof. Dr. med. Monika Brüggemann

Universitätsklinikum Schleswig-Holstein
Klinik für Innere Medizin II
Hämatologie und Onkologie
Langer Segen 8-10
24105 Kiel
m.brueggemann@med2.uni-kiel.de

Prof. Dr. med. Alexander W. Hauswirth

Medizinische Universität Wien
Innere Medizin I/Abteilung f.
Hämatologie u. Hämostaseologie
Währinger Gürtel 18-20
A-1090 Wien
alexander.hauswirth@meduniwien.ac.at

PD Dr. Urs Schanz

Universitätsspital Zürich
Klinik für Hämatologie
Rämistr. 100
CH-8091 Zürich
urs.schanz@usz.ch

Dr. Sigrid Machherndl-Spandl

Ordensklinikum Linz Elisabethinen
Interne 1 - Hämatologie mit
Stammzelltransplantation, Hämostaseologie
und medizinische Onkologie
Fadingerstr. 1
A-4020 Linz
sigrid.machherndl-spandl@ordensklinikum.at

Prof. Dr. med. Matthias Stelljes

Medizinische Klinik A /
Hämatologie und Onkologie
Universitätsklinikum Münster
Domagkstr. 9a
48149 Münster
Matthias.Stelljes@ukmuenster.de

Prof. Dr. med. Max Topp

Universitätsklinikum Würzburg
Medizinische Klinik und Poliklinik II
Oberdürrbachstr. 6
97080 Würzburg
topp_m@ukw.de

16 Disclosures

Conflicts of interest can be found in the [full German version of the guideline](#).